Monash antibodies, Adelaide protein gels
Thursday, 22 January, 2009
Monash University has signed a deal with Danish pathology and cancer diagnostics specialist Dako to develop monoclonal antibodies for cancer research and treatment.
The Monash Antibody Technologies Facility (MATF), opened in September last year, will develop high-affinity antibodies for what it called “global commercialisation opportunities”.
MATF director Alan Sawyer said in a statement that the collaboration was part of the facility’s vision to provide the international research and diagnostics community with the best reagents possible.
Meanwhile, the Adelaide Proteomics Centre has decided to adopt publicly listed Fluorotechnics’ range of 2D gels and dyes for protein detection.
The centre has also agreed to become Fluorotechnics’ Australian reference customer and promote the company’s gels in Australia and internationally.
Depression impacts energy at a cellular level, researchers find
Depression symptoms may be rooted in fundamental changes in the way brain and blood cells use...
Are discarded peanut shells the affordable and sustainable path to graphene?
Australian researchers have produced small quantities of high-quality graphene via a new process...
Aussie biotech to manufacture mRNA paediatric brain cancer vaccines
A Queensland-based biotechnology company will manufacture personalised mRNA paediatric brain...
